Factors limiting clinical efficacy of EpCAM-targeting antibodies include poor penetration in tumor mass, insufficient anti-tumor action, and lack of patient stratification to identify potential responders prior to therapy [35]. This evidence concerns the gene EPCAM and neoplasm.